Assertio Holdings Inc
NASDAQ:ASRT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ABM Investama Tbk PT
IDX:ABMM
|
ID |
Assertio Holdings Inc
No
Economic Moat
Assertio Holdings Inc lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Assertio Holdings Inc
Competitive Advantages
Wide Economic Moat Companies
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
NVIDIA Corp
NVDA
|
$178.1 |
+0.8%
|
$4.3T | Wide |
|
|
|
Apple Inc
AAPL
|
$253.5 |
+2.1%
|
$3.7T | Wide |
|
|
|
Alphabet Inc
GOOGL
|
$305.46 |
-0.2%
|
$3.7T | Wide |
|
|
|
Microsoft Corp
MSFT
|
$372.29 |
+1%
|
$2.8T | Wide |
|
|
|
Amazon.com Inc
AMZN
|
$213.77 |
+1.6%
|
$2.3T | Wide |
|
|
|
Taiwan Semiconductor Manufacturing Co Ltd
2330
|
NT$1 945 |
+2.5%
|
$1.6T | Wide |
|
|
|
Meta Platforms Inc
META
|
$575.05 |
+0.1%
|
$1.5T | Wide |
|
|
|
Broadcom Inc
AVGO
|
$333.97 |
-1.9%
|
$1.6T | Wide |
|
|
|
Walmart Inc
WMT
|
$122.49 |
+0.6%
|
$976.3B | Wide |
|
|
|
Eli Lilly and Co
LLY
|
$931.09 |
-1.3%
|
$880.2B | Wide |
| Company | Last Price | Price Change | Market Cap | Economic Moat | ||
|---|---|---|---|---|---|---|
|
|
|
AstraZeneca PLC
AZN
|
GBX14 958 |
-0.1%
|
$313B | Wide |
|
|
|
Kweichow Moutai Co Ltd
600519
|
¥1 456.75 |
+1.7%
|
$265B | Wide |
|
|
|
Novo Nordisk A/S
NOVO B
|
kr241.75 |
-1.9%
|
$169.3B | Wide |
|
|
|
Zhongji Innolight Co Ltd
300308
|
¥685.19 |
+2.5%
|
$110.6B | Wide |
|
|
|
Hindustan Aeronautics Ltd
HAL
|
₹3 876 |
+0.8%
|
$28.5B | Wide |
|
|
|
Trent Ltd
TRENT
|
₹3 940 |
-0.2%
|
$15.4B | Wide |
|
|
|
ABB India Ltd
ABB
|
₹6 512 |
+2%
|
$15.2B | Wide |
|
|
|
Cummins India Ltd
CUMMINSIND
|
₹4 719 |
+0.2%
|
$14.4B | Wide |
|
|
|
BSE Ltd
BSE
|
₹3 192.6001 |
+1%
|
$14.3B | Wide |
|
|
|
Solar Industries India Ltd
SOLARINDS
|
₹13 682 |
+0.8%
|
$13.6B | Wide |
Assertio Holdings Inc
Glance View
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.
The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.
Note: This research does not account for survivorship bias. Past performance is not indicative of future results.
Economic Moat
